LCAR-B38M CAR-T cell injection
Phase 1/2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory or Relapsed Multiple Myeloma
Conditions
Refractory or Relapsed Multiple Myeloma
Trial Timeline
Oct 2, 2015 → Dec 31, 2023
NCT ID
NCT03090659About LCAR-B38M CAR-T cell injection
LCAR-B38M CAR-T cell injection is a phase 1/2 stage product being developed by Legend Biotech for Refractory or Relapsed Multiple Myeloma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03090659. Target conditions include Refractory or Relapsed Multiple Myeloma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory or Relapsed Multiple Myeloma were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
4
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03090659 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Refractory or Relapsed Multiple Myeloma